Responding quickly to an important medical need has been the commitment of APTEEUS for several years. Many rare genetic diseases are life-threatening for children, yet their diseases are overlooked for lack of economic sustainability.
Faced with the sudden onset and rapid spread of COVID19, we, the citizens of the world, have been totally helpless. Our efforts to develop an effective antiviral drug will pay off in a few years. For an immediate response, it was necessary to look at the existing international therapeutic arsenal. Are there any drugs indicated for other diseases capable of limiting the infection of the SARS2 corona virus? The Task Force of the Institut Pasteur de Lille is currently developing an in vitro test to test on the virus all the molecules already approved for use in humans from the APTEEUS collection. This initiative could result in the rapid availability of a drug for those infected. There are already around ten clinical trials in the world studying mainly the effect of available antivirals.
